Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Ocul Immunol Inflamm ; 30(5): 1136-1141, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1784138

ABSTRACT

PURPOSE: To highlight the potential risk of herpetic eye disease (HED) reactivation following COVID-19 vaccine. METHODS: Retrospective analysis of all patients who presented with HED within 28 days post-first dose COVID-19 vaccination. RESULTS: Eleven eyes (n = 10 patients) were included. The mean interval between COVID-19 vaccination and ocular symptoms/signs was 12.3 ± 10.3 days. Four (40%) patients presented with HSV keratitis, and six (60%) patients presented with VZV keratitis (five had concurrent other signs of herpes zoster ophthalmicus). Common ocular signs included multiple scattered dendritic/pseudodendritic corneal epitheliopathy (90.9%), anterior uveitis (63.6%), and endothelitis (27.3%). All cases were successfully treated with topical and systemic antiviral treatment and/or topical corticosteroids (mean healing time = 3.9 ± 1.6 weeks). CONCLUSIONS: Our case series highlights the potential temporal association between HED and COVID-19 vaccine. Prophylactic antiviral treatment is recommended in patients with a history of HED prior to COVID-19 vaccination.


Subject(s)
COVID-19 Vaccines , COVID-19 , Herpes Zoster Ophthalmicus , Keratitis, Herpetic , Humans , Antiviral Agents/therapeutic use , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Glucocorticoids/therapeutic use , Herpes Zoster Ophthalmicus/chemically induced , Herpes Zoster Ophthalmicus/diagnosis , Herpes Zoster Ophthalmicus/drug therapy , Keratitis, Herpetic/chemically induced , Keratitis, Herpetic/diagnosis , Keratitis, Herpetic/drug therapy , Retrospective Studies , United Kingdom/epidemiology
4.
Ther Adv Ophthalmol ; 12: 2515841420964099, 2020.
Article in English | MEDLINE | ID: covidwho-885970
SELECTION OF CITATIONS
SEARCH DETAIL